The mission of the UCSF-Gladstone Center for AIDS Research (CFAR) is to promote multidisciplinary research at the intersection of the basic, clinical, and behavioral-epidemiological sciences with the goal of ending the global HIV epidemic. To fulfill its mission, CFAR collaborates with UCSF's AIDS Research Institute and the Center for AIDS Prevention Studies (CAPS), as well as the newly funded amfAR Institute for HIV Cure Research, to coordinate a multi-pronged program that aims to: 1) Provide administrative and scientific leadership through a proactive planning process that identifies the most important challenges emerging at the cutting edge of HIV research 2) Identify, mentor, and support a highly skilled, diverse, and thoughtful next generation of HIV investigators by providing a strong mentoring program unique to UCSF and through a California-funded Health Disparities Core linked to CFAR 3) Conduct a dynamic pilot grants program to accelerate discovery 4) Maintain an outstanding set of scientific cores to extend the reach of Center investigators' research 5) Ensure our programs support major NIH-funded HIV/AIDS research programs and OAR priorities 6) Confront domestic prevention and treatment disparities through effective local collaborations 7) Direct CFAR's research and capacity building programs to international sites where the epidemic is hitting the hardest 8) Engage the communities we serve through a set of novel alliances involving Project Inform, the Forum for Collaborative HIV Research, and UCSF's Science and Health Education Partnership 9) Forge effective inter-CFAR collaborations to nucleate research teams across different disciplines and sites to address all dimensions of these identified challenges CFAR brings value by creating and sustaining a true community of HIV/AIDS science. CFAR is proud of its accomplishments in the last four years including: the publication of 791 papers; the mentoring of 69 early career investigators; the award of $6.1 million to support 79 CFAR grants and supplements; the success of recent CFAR awardees in winning more than $106.7 million dollars in peer-reviewed, HIV-related funding; and our continuing engagement in the planning and organization of the East Africa Collaborative Scientific Symposium and Sub-Saharan Africa CFAR Conferences featuring the work of African scientists. However, much work remains to be done. CFAR looks forward to helping stimulate progress on multiple scientific fronts including increasing access to implementation science methods, driving progress in HIV eradication, increasing access to proven biomedical approaches to HIV prevention and addressing disparities in HIV care and treatment within resource-limited communities in the Bay Area and abroad.

Public Health Relevance

The mission of the UCSF-Gladstone Center for AIDS Research (CFAR) is to promote multidisciplinary research at the intersection of the basic, clinical, and behavioral-epidemiological sciences with the goal of ending the global HIV epidemic. To fulfill its mission, CFAR collaborates with UCSF's AIDS Research Institute and the Center for AIDS Prevention Studies (CAPS), as well as the newly funded amfAR Institute for HIV Cure Research, to coordinate a multi-pronged program that aims to: Provide administrative and scientific leadership through a proactive planning process that identifies the most important challenges emerging at the cutting edge of HIV research; Identify, mentor, and support a highly skilled, diverse, and thoughtful next generation of HIV investigators by providing a strong mentoring program unique to UCSF and through a California-funded Health Disparities Core linked to CFAR; Conduct a dynamic pilot grants program to accelerate discovery; Maintain an outstanding set of scientific cores to extend the reach of Center investigators' research; Ensure our programs support major NIH-funded HIV/AIDS research programs and OAR priorities; Confront domestic prevention and treatment disparities through effective local collaborations; Direct CFAR's research and capacity building programs to international sites where the epidemic is hitting the hardest Engage the communities we serve through a set of novel alliances involving Project Inform, the Forum for Collaborative HIV Research, and UCSF's Science and Health Education Partnership; and Forge effective inter-CFAR collaborations to nucleate research teams across different disciplines and sites to address all dimensions of these identified challenges. CFAR brings value by creating and sustaining a true community of HIV/AIDS science. CFAR is proud of its accomplishments in the last four years including: the publication of 791 papers; the mentoring of 69 early career investigators; the award of $6.1 million to support 79 CFAR grants and supplements; the success of recent CFAR awardees in winning more than $106.7 million dollars in peer- reviewed, HIV-related funding; and our continued engagement in East Africa. CFAR will to helping stimulate progress on multiple scientific fronts including increasing access to implementation science methods, driving progress in HIV eradication, increasing access to proven biomedical approaches to HIV prevention and addressing disparities in HIV care and treatment within resource-limited communities in the Bay Area and abroad.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027763-27
Application #
9502898
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Beaubien, Candice M
Project Start
1997-03-01
Project End
2022-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
27
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Kattah, Michael G; Milush, Jeffrey M; Burt, Trevor et al. (2018) Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. Clin Transl Gastroenterol 9:143
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
El-Sadr, Wafaa M; Goosby, Eric (2018) Building on the HIV platform: tackling the challenge of noncommunicable diseases among persons living with HIV. AIDS 32 Suppl 1:S1-S3
Lidofsky, Anna; Holmes, Jacinta A; Feeney, Eoin R et al. (2018) Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. J Infect Dis 218:1394-1403
Dunkley, Emma; Ashaba, Scholastic; Burns, Bridget et al. (2018) ""I beg you…breastfeed the baby, things changed"": infant feeding experiences among Ugandan mothers living with HIV in the context of evolving guidelines to prevent postnatal transmission. BMC Public Health 18:188
Streubel, Gundula; Watson, Ariane; Jammula, Sri Ganesh et al. (2018) The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells. Mol Cell 70:371-379.e5
Carrico, Adam W; G?mez, Walter; Jain, Jennifer et al. (2018) Randomized controlled trial of a positive affect intervention for methamphetamine users. Drug Alcohol Depend 192:8-15
Cary, Daniele C; Peterlin, B Matija (2018) Natural Products and HIV/AIDS. AIDS Res Hum Retroviruses 34:31-38
Buggert, Marcus; Nguyen, Son; Salgado-Montes de Oca, Gonzalo et al. (2018) Identification and characterization of HIV-specific resident memory CD8+ T cells in human lymphoid tissue. Sci Immunol 3:
Holmes, Charles B; Sikazwe, Izukanji; Sikombe, Kombatende et al. (2018) Estimated mortality on HIV treatment among active patients and patients lost to follow-up in 4 provinces of Zambia: Findings from a multistage sampling-based survey. PLoS Med 15:e1002489

Showing the most recent 10 out of 1541 publications